Table 1.
Patient characteristics for MNf and TA groups are presented [sex, age, ECOG performance status, chemotherapy, biologic agent, disease response based on the RECIST criteria, KRAS status, NRAS status, BRAF status, mismatch repair (MMR) status, location of the primary lesion, number of metastatic sites].
| MNf | p | TA | P | ||||
|---|---|---|---|---|---|---|---|
| mCRC | laRC | mCRC | laRC | ||||
| Total Number of patient | 55 | 21 | 23 | 5 | |||
| Sex, n (%) | Males | 28 (50.9) | 16 (76.2) | 0.068 | 9 (39.0) | 3 (60.0) | 0.393 |
| Females | 27 (49.1) | 5 (23.8) | 14 (61.0) | 2 (40.0) | |||
| Age, n (%) | ≤40 | 0 (0.0) | 1 (4.8) | 0.435 | 1 (4.8) | 1 (20.0) | 0.173 |
| 41-55 | 13 (23.6) | 5 (23.8) | 5 (23.8) | 3 (60.0) | |||
| 56-70 | 24 (43.6) | 8 (38.1) | 8 (38.1) | 1 (20.0) | |||
| 70+ | 18 (32.7) | 7 (33.3) | 7 (33.3) | 0 (0.0) | |||
|
ECOG performance
status, n (%) |
0 | 22 (95.6) | 47 (85.5) | 0.199 | 19 (86.4) | 5 (100.0) | 0.08 |
| 1 | 1 (4.3) | 8 (14.5) | 3 (13.6) | 0 (0.0) | |||
| Chemotherapy, n(%) | FOLFOX | 29 (52.7) | 12 (57.0) | 0.98* | 10 (43.5) | 4 (80.0) | 0.14* |
| FOLFIRI | 22 (40.0) | 0 (0.0) | 13 (36.3) | 0 (0.0) | |||
| FOLFOXIRI | 4 (7.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |||
| CAPOX | 0 (0.0) | 9 (43.0) | 0 (0.0) | 1 (20.0) | |||
| Biological agent, n (%) | Bevacizumab | 19 (34.5) | NA | 7 (30.0) | NA | ||
| Aflibercept | 5 (9.0) | 5 (22.0) | |||||
| Cetuximab | 9 (16.5) | 6 (26.0) | |||||
| Panitumumab | 7 (12.7) | 0 (0.0) | |||||
| No agent | 15 (27.2) | 5 (22.0) | |||||
| Disease response, n (%) | Progression | 13 (23.6) | 2 (9.8) | 0.08 | 6 (20.0) | 0 (0.0) | 0.25 |
| Stable disease | 18 (32.7) | 5 (23.8) | 7 (30.0) | 3 (60.0) | |||
| Partial response | 23 (41.8) | 11 (52.4) | 9 (40.0) | 1 (20.0) | |||
| Complete response | 1 (1.8) | 3 (14.3) | 1 (4.0) | 1 (20.0) | |||
| KRAS, n (%) | WT | 25 (45.5) | 9 (39.1) | 0.61** | Unknown | ||
| exon 2 mut | 18 (32.7) | 6 (26.1) | *** | ||||
| exon 3 mut | 0 (0.0) | 0 (0.0) | |||||
| exon 4 mut | 1 (1.8) | 1 (4.3) | |||||
| Unknown | 11 (20.0) | 7 (30.4) | |||||
| NRAS, n (%) | WT | 42 (76.4) | 15 (65.2) | 0.31** | Unknown | ||
| Mutation | 2 (3.6) | 2 (8.7) | |||||
| Unknown | 11 (20.0) | 6 (26.1) | |||||
| BRAF, n (%) | WT | 41 (74.5) | 15 (65.2) | 0.48** | Unknown | ||
| V600E mut | 4 (7.3) | 1 (4.3) | |||||
| Unknown | 11 (20.0) | 7 (30.4) | |||||
|
Mismatch repair
status, n (%) |
Proficient | 12 (58.2) | 21 (91.3) | 0.01 | Unknown | ||
| Deficient | 2 (3.6) | 1 (4.3) | |||||
| Unknown | 21 (38.2) | 1 (4.2) | |||||
|
Location of
primary lesion, n (%) |
Left | 42 (76.4) | 19 (83.0) | 0.54 | 21 (100) | 5 (100) | NA |
| Right | 13 (23.6) | 4 (17.0) | 0 (0.0) | 0 (0.0) | |||
|
Metastatic sites
[median/mean (range)] |
Liver | 3.6/4.4 (0–20) |
NA | NA*** | |||
| Lung | 3.2/3.5 (0–11) |
||||||
| Lymph nodes | 0/3.2 (0–14) |
0/3.2 (0–6) | |||||
| Peritoneum | 0/3.6 (0–8) |
||||||
*p-values from comparison of FOLFOX with the rest of chemotherapies, *p-values from comparison between wild-type and mutations,***Unknown: There were no data , ****NA, not applicable.